Oral contraceptives beneficial effects

Many studies have also shown a duration-related protective effect of combined oral contraceptives on endometrial cancer, the risk before age 60 being reduced by 38% after 2 years of use and up to a 70% reduction after 12 years (114). This beneficial effect continued for at least 15 years after the end of use. As with ovarian cancer, the CASH study results suggest that the lower-dose combined oral contraceptives have a protective effect similar to that of the higher-dose tablets (115). 

Although some studies have shown that combined oral contraceptives increase bone mineral density, the available evidence suggests that any beneficial effect is rather... 

The current consensus is that the contemporary low-dose preparations pose minimal risks in women who have no predisposing risk factors and, in fact, may provide certain beneficial health effects (e.g., protection against endometrial and ovarian cancer). Oral contraceptive pills have been associated with increased risk for myocardial infarction, stroke, and venous thromboembolism. However, studies have been published that suggest that these risks are minimal in appropriately chosen low-risk women. 

COMBINATION ORAL CONTRACEPTIVES The consensus is that low-dose oral contraceptives pose minimal health risks in women who have no predisposing risk factors and also provide many beneficial health effects. 

Atorva tatin and ro uva tatin may modestly increase the plasma levels of combined oral contraceptives. Rosuvastatin pharmacokinetics and lipid-lowering effects were unaffected by an oral contraceptive containing ethinylestradiol and norgestimate. The pharmacokinetics of a single dose of pravastatin were also unaffected by combined oral contraceptives. However, norethisterone abolished the beneficial effects of atorvastatin and/or estradiol on the lipid profile. 

---